CYT X300 / Cytospire Therapeutics - LARVOL DELTA

CYT X300, a novel EGFR x pan-gamma delta T cell engager for the treatment of solid tumors (AACR 2026) - "Studies in non-human primates have shown that CYT X300 is very well tolerated and does not induce the severe toxicities that have been a hallmark of EGFR x CD3 engagers.Based on these data, CYT X300 is currently being advanced through IND-enabling preclinical studies and GMP manufacturing. A first-in-human clinical study is being planned to evaluate CYT X300 as a treatment for a range of EGFR-positive solid tumors including colorectal, head and neck and non-small cell lung cancers."

First-in-human • IO biomarker • Late-breaking abstract • Hematological Malignancies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • IL6 • TNFA